This study is in progress, not accepting new patients
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Summary
- Eligibility
- for people ages 50-90 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Biogen
- ID
- NCT04241068
- Phase
- Phase 3 Alzheimer's Disease Research Study
- Study Type
- Interventional
- Participants
- About 1696 people participating
- Last Updated